Nice find. A very interesting document. Succinctly and...

Nice find. A very interesting document. Succinctly and professionally summarises the recent research and strategy. Feels like they are expecting a bit of attention soon.

This is pretty bullish on page 7:

"IDX is a clinically ready, small molecule with FDA IND approval with a unique opportunity to help these SARS-COV2 infected patients with severe inflammation symptoms and prevent or reduce Sepsis"

I used to think a wholesale acquisition would be the likely exit for NOX, but yes the pillars strategy and recent GK talk seems to be positioning for partnerships in the shorter term anyway.